Jazz Pharmaceuticals, Inc. (JAZZ)

DarthMaul09 (98.61) Submitted: 11/25/2009 12:54:59 AM : Start Price: $7.79 JAZZ Score: +2.50

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

I doubt that these products are good enough to warrant the optimism that was reflected in the stock rise today. The government formulary will probably only include: Aspirin, Lithium, Valium, and Vit D. All are cheap, generic and in common use. Back to the future of health care.

cashsage (77.50) Submitted: 11/7/2009 1:45:18 PM : Start Price: $6.96 JAZZ Score: -6.16

JAZZ has a too high valuation compared to its sales potential. It is also one of the most loss making companies. Its stock price may be more than halved.

geodawg2000 (< 20) Submitted: 6/16/2009 10:41:38 PM : Start Price: $3.77 JAZZ Score: -78.99

this was too quick of a run. Especially only after a trail run.